BeyondSpring Inc. (NASDAQ:BYSI) Q2 2020 Earnings Conference Call - Final Transcript

Sep 03, 2020 • 08:00 am ET


BeyondSpring Inc. (NASDAQ:BYSI) Q2 2020 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good morning, and welcome to BeyondSpring's Second Quarter 2020 Financial Results Conference Call. My name is Kevin, and I will be your operator for today's conversation. [Operator Instructions].

At this time, I would like to turn the call over to Scott Eckstein, Vice President at KCSA Strategic Communications. Scott, please go ahead.

Scott Eckstein

Thank you for joining today's call.

I would like to advise listeners that comments made during today's call may reflect forward-looking statements that are related to such matters as BeyondSpring's clinical and preclinical research and development activities and results, regulatory and commercial plans, industry trends, market potential, collaborative initiatives, and financial projections, among others. While management believes that its assumptions, expectations and projections are reasonable in view of the currently available information, you are cautioned not to place undue reliance on these forward-looking statements. The company's actual results may differ materially from those discussed during this call for a variety of reasons, including those described in the forward-looking statements and Risk Factors sections of the company's 20-F and in other filings with the SEC, which are available on the Investors section of BeyondSpring's website.

Joining us on today's call is Dr. Lan Huang, BeyondSpring Co-Founder, Chairman and Chief Executive Officer; Dr. Ramon Mohanlal, Executive Vice President, Research and Development and Chief Medical Officer; Richard Daly, Chief Operating Officer; and Edward Liu, Chief Financial Officer.

It is now my pleasure to turn the call over to Dr. Lan Huang. Lan?

Lan Huang

Yeah. Thank you so much, Scott. Good morning, ladies and gentlemen, thank you for joining today's call.

BeyondSpring's mission has been to develop innovative, transformative medicines that improve clinical outcomes in high unmet medical needs for the global market. With our lead asset, first-in-class agent Plinabulin in late stage developments in two large oncology market opportunities for chemotherapy-induced neutropenia or CIN prevention and non-small cell lung cancer treatment, we believe that we are at a significant inflection point that will potentially result in helping many patients in need and realizing tremendous value for our shareholders. This is the combination of 10 years of hard work at BeyondSpring with our dedicated and experienced team and our partners, globally.

In addition, we have a developing clinical and preclinical pipeline with plinabulin in multiple I/O combo cancer indications, three preclinical I/O agents and world leading targeted protein degradation, TPD platform to fuel future growth. Dr. Hershko, Nobel prize winner in the field is our scientific advisor.

Finally, we have developed global capabilities through strong clinical and regulatory network and developing commercial infrastructure to drive ongoing innovation. For Plinabulin's first indication, CIN, we expect to file NDA to the US FDA by the end of 2020. We have initiated rolling NDA submission for China NMPA in quarter one, 2020. CIN indication has only one drug G-CSF approved in the last 30 years. G-CSF class, which has annual revenue of over $9 billion globally and over $7 billion in the US alone.

Even with the use of G-CSF, cancer patients undergoing chemo still experiencing over